1. Home
  2. PRTA vs IDR Comparison

PRTA vs IDR Comparison

Compare PRTA & IDR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Prothena Corporation plc

PRTA

Prothena Corporation plc

N/A

Current Price

$8.36

Market Cap

458.4M

Sector

Health Care

ML Signal

N/A

Logo Idaho Strategic Resources Inc.

IDR

Idaho Strategic Resources Inc.

N/A

Current Price

$28.76

Market Cap

509.9M

ML Signal

N/A

Company Overview

Basic Information
Metric
PRTA
IDR
Founded
2012
1996
Country
Ireland
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Precious Metals
Sector
Health Care
Basic Materials
Exchange
Nasdaq
Nasdaq
Market Cap
458.4M
509.9M
IPO Year
2013
2000

Fundamental Metrics

Financial Performance
Metric
PRTA
IDR
Price
$8.36
$28.76
Analyst Decision
Buy
Analyst Count
9
0
Target Price
$19.00
N/A
AVG Volume (30 Days)
307.4K
189.7K
Earning Date
05-07-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
70.15
EPS
0.26
0.63
Revenue
$814,000.00
$42,406,253.00
Revenue This Year
$1,111.38
$25.52
Revenue Next Year
N/A
N/A
P/E Ratio
$34.35
$49.06
Revenue Growth
N/A
64.59
52 Week Low
$7.73
$26.02
52 Week High
$11.80
$54.70

Technical Indicators

Market Signals
Indicator
PRTA
IDR
Relative Strength Index (RSI) 42.61 39.45
Support Level $8.62 $28.95
Resistance Level $9.36 $35.52
Average True Range (ATR) 0.33 1.41
MACD -0.08 -0.30
Stochastic Oscillator 8.60 2.93

Price Performance

Historical Comparison
PRTA
IDR

About PRTA Prothena Corporation plc

Prothena Corp PLC is a late-stage clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. Prothena is developing and applying its proprietary CYTOPE technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. The company's pipeline includes both wholly-owned and partnered programs like Prasinezumab, Coramitug (PRX004), BMS-986446 (PRX005), PRX019, TDP-43 CYTOPE, and PRX012-TfR, being developed for the potential treatment of Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases.

About IDR Idaho Strategic Resources Inc.

Idaho Strategic Resources Inc is a vertically integrated, operating junior mining company. The Company's primary business is exploring for, developing, and extracting gold, and to a lesser extent, silver, and base metal mineral resources in the greater Coeur d'Alene Mining District of North Idaho. The Company produces gold at the Golden Chest Mine located in the Murray Gold Belt area of the world-class Coeur d'Alene Mining District, north of the prolific Silver Valley.

Share on Social Networks: